Literature DB >> 28099264

Post-treatment 18F-FDG-PET/CT versus contrast-enhanced CT in patients with oropharyngeal squamous cell carcinoma: comparative effectiveness study.

Mehdi Taghipour1, Esther Mena, Matthew J Kruse, Sara Sheikhbahaei, Rathan M Subramaniam.   

Abstract

OBJECTIVE: To compare the accuracy of same-day therapy-assessment PET/computed tomography (PET/CT) and conventional contrast-enhanced computed tomography (CECT) in patients with oropharyngeal squamous cell carcinoma (OPSCC).
METHODS: A total of 110 (95 men and 15 women; mean age 59 years) patients with biopsy-proven OPSCC were evaluated with same-day PET/CT and CECT pair scans as part of follow-up therapy assessment. Scans were performed within 6 months after the completion of primary treatment (median time: 3.1 months; range: 0.5-6 months). PET/CT and CECT scans were reviewed retrospectively for residual primary site disease, and right and left cervical lymph node involvement. Histopathology or 6 month clinical/imaging follow-up were used as the gold standard. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated for the primary site and cervical nodal disease.
RESULTS: Of 110 OPSCC patients, 90.9% were human papilloma virus positive, 80.8% were stage 4, and 76.4% received chemoradiation as the primary treatment. The sensitivity, specificity, PPV, NPV, and accuracy of PET/CT and CECT were similar in the evaluation of the primary cancer site (PET/CT: 75.0, 91.5, 25.0, 99.0, and 90.9, respectively, versus CECT: 75.0, 90.6, 23.1, 99.0, and 90.0, respectively). In evaluating cervical lymph node involvement, PET/CT appeared to have higher accuracy (96.8 vs. 81.7%), specificity (97.7 vs. 81.7%), and PPV (45.8 vs. 16.5%), comparable NPV (99.4% for both), and lower sensitivity (65 vs. 75%) compared with same-day CECT.
CONCLUSION: Same-day PET/CT and CECT scans had comparable accuracy in the evaluation of primary tumor sites after completion of therapy in patients with OPSCC. PET/CT showed higher accuracy in the evaluation of cervical lymph node involvement.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28099264      PMCID: PMC5360462          DOI: 10.1097/MNM.0000000000000639

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  37 in total

1.  Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: the role of US, MRI and FDG-PET/TC scans to assess residual neck disease.

Authors:  Raul Pellini; Valentina Manciocco; Mario Turri-Zanoni; Antonello Vidiri; Giuseppe Sanguineti; Laura Marucci; Rosa Sciuto; Renato Covello; Isabella Sperduti; Ramy Kayal; Vincenzo Anelli; Barbara Pichi; Giuseppe Mercante; Giuseppe Spriano
Journal:  J Craniomaxillofac Surg       Date:  2014-07-09       Impact factor: 2.078

2.  Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis.

Authors:  Tejpal Gupta; Zubin Master; Sadhana Kannan; Jai Prakash Agarwal; Sarbani Ghsoh-Laskar; Venkatesh Rangarajan; Vedang Murthy; Ashwini Budrukkar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-19       Impact factor: 9.236

3.  Imaging modality utilization trends in patients with stage III-IV oropharyngeal squamous cell carcinoma.

Authors:  Yukako Ichimiya; Krishna Alluri; Charles Marcus; Simon Best; Christine H Chung; Rathan M Subramaniam
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

4.  Risk stratification of metastatic neck nodes by CT and PET in patients with head and neck cancer receiving definitive radiotherapy.

Authors:  Ying-Chun Lin; Shang-Wen Chen; Te-Chun Hsieh; Kuo-Yang Yen; Shih-Neng Yang; Yao-Ching Wang; Chia-Hung Kao
Journal:  J Nucl Med       Date:  2015-01-22       Impact factor: 10.057

5.  FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy.

Authors:  Mehdi Taghipour; Sara Sheikhbahaei; Rick Wray; Nishant Agrawal; Jeremy Richmon; Hyunseok Kang; Rathan M Subramaniam
Journal:  AJR Am J Roentgenol       Date:  2016-03-21       Impact factor: 3.959

6.  Improvement in the detection of locoregional recurrence in head and neck malignancies: F-18 fluorodeoxyglucose-positron emission tomography/computed tomography compared to high-resolution contrast-enhanced computed tomography and endoscopic examination.

Authors:  Balasubramanya Rangaswamy; M Reza Fardanesh; Eric M Genden; Eunice E Park; Girish Fatterpekar; Zara Patel; Jongho Kim; Peter M Som; Lale Kostakoglu
Journal:  Laryngoscope       Date:  2013-04-01       Impact factor: 3.325

Review 7.  Value of imaging in head and neck tumors.

Authors:  Alexander J Antoniou; Charles Marcus; Rathan M Subramaniam
Journal:  Surg Oncol Clin N Am       Date:  2014-08-03       Impact factor: 3.495

8.  Treatment response in the neck: p16+ versus p16- oropharyngeal cancer.

Authors:  Daisy Mak; Rodney J Hicks; Danny Rischin; Ben Solomon; Lester Peters; Mathias Bressel; Richard J Young; June Corry
Journal:  J Med Imaging Radiat Oncol       Date:  2013-01-30       Impact factor: 1.735

Review 9.  A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy.

Authors:  M G Isles; C McConkey; H M Mehanna
Journal:  Clin Otolaryngol       Date:  2008-06       Impact factor: 2.597

10.  Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States.

Authors:  Martin Steinau; Mona Saraiya; Marc T Goodman; Edward S Peters; Meg Watson; Jennifer L Cleveland; Charles F Lynch; Edward J Wilkinson; Brenda Y Hernandez; Glen Copeland; Maria S Saber; Claudia Hopenhayn; Youjie Huang; Wendy Cozen; Christopher Lyu; Elizabeth R Unger
Journal:  Emerg Infect Dis       Date:  2014-05       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.